Multifunctional targetable liposomal drug delivery system in the management of leukemia: Potential, opportunities, and emerging strategies

被引:11
作者
Pardhi, Ekta [1 ]
Yadav, Rati [1 ]
Chaurasiya, Akash [2 ]
Madan, Jitender [1 ]
Guru, Santosh Kumar [3 ]
Singh, Shashi Bala [3 ]
Mehra, Neelesh Kumar [1 ,4 ]
机构
[1] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut, Pharmaceut Nanotechnol Res Lab, Hyderabad 500037, Telangana, India
[2] BITS Pilani, Dept Pharmaceut, Hyderabad Campus, Hyderabad, India
[3] Natl Inst Pharmaceut Educ & Res NIPER, Dept Biol Sci, Hyderabad 500037, Telangana, India
[4] Govt India, Minist Chem & Fertilizers, Natl Inst Pharmaceut Educ & Res NIPER, Pharmaceut Nanotechnol Res Lab,Dept Pharmaceut, Hyderabad 500037, Telangana, India
关键词
Leukemia; Liposomes; Multifunctional; Targeting; Regulatory perspective; ACUTE MYELOID-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HAIRY-CELL LEUKEMIA; P-SITE INHIBITOR; STEM-CELLS; GEMTUZUMAB OZOGAMICIN; CO-DELIVERY; IN-VITRO; LIPOPOLYPLEX NANOPARTICLES;
D O I
10.1016/j.lfs.2023.121771
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The concern impeding the success of chemotherapy in leukemia treatment is descending efficacy of drugs because of multiple drug resistance (MDR). The previous failure of traditional treatment methods is primarily responsible for the present era of innovative agents to treat leukemia effectively. The treatment option is a chemotherapeutic agent in most available treatment strategies, which unfortunately leads to high unavoidable toxicities. As a result of the recent surge in marketed products, theranostic nanoparticles, i.e., multifunctional targetable liposomes (MFTL), have been approved for improved and more successful leukemia treatment that blends therapeutic and diagnostic characteristics. Since they broadly offer the required characteristics to get past the traditional/previous limitations, such as the absence of site-specific anti-cancer therapeutic delivery and ongoing real-time surveillance of the leukemia target sites while administering therapeutic activities. To prepare MFTL, suitable targeting ligands or tumor-specific antibodies are required to attach to the surface of the liposomes. This review exhaustively covered and summarized the liposomal-based formulation in leukemia treatment, emphasizing leukemia types; regulatory considerations, patents, and clinical portfolios to overcome clinical translation hurdles have all been explored.
引用
收藏
页数:25
相关论文
共 217 条
[1]  
accessmedicine, 2023, Malignancies of Lymphoid Cells | Harrison's Principles of Internal Medicine, 19e | AccessMedicine | McGraw Hill Medical
[2]   Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines [J].
Ailles, LE ;
Gerhard, B ;
Hogge, DE .
BLOOD, 1997, 90 (07) :2555-2564
[3]   Venetoclax-containing regimens in acute myeloid leukemia [J].
Aldoss, Ibrahim ;
Pullarkat, Vinod ;
Stein, Anthony S. .
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[4]   Haematological cancer and quality of life: a systematic literature review [J].
Allart-Vorelli, P. ;
Porro, B. ;
Baguet, F. ;
Michel, A. ;
Cousson-Gelie, F. .
BLOOD CANCER JOURNAL, 2015, 5 :e305-e305
[5]   Nanomedicines for overcoming biological barriers [J].
Alonso, MJ .
BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (03) :168-172
[6]   Targeting the IDH2 Pathway in Acute Myeloid Leukemia [J].
Amaya, Maria L. ;
Pollyea, Daniel A. .
CLINICAL CANCER RESEARCH, 2018, 24 (20) :4931-4936
[7]   Characterization of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia [J].
Amin, HM ;
Ergin, M ;
Denning, MF ;
Quevedo, ME ;
Alkan, S .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (03) :552-562
[8]   LIPOSOME ELECTROFORMATION [J].
ANGELOVA, MI ;
DIMITROV, DS .
FARADAY DISCUSSIONS, 1986, 81 :303-+
[9]   Gemtuzumab ozogamicin for acute myeloid leukemia [J].
Appelbaum, Frederick R. ;
Bernstein, Irwin D. .
BLOOD, 2017, 130 (22) :2373-2376
[10]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405